Patients who have had acute allergic-like reactions to nonionic iodinated contrast material rarely develop serious long-term problems and can be treated safely with commonly used medications, according to a study conducted by researchers at the University of Michigan Hospitals in Ann Arbor.
Patients who have had acute allergic-like reactions to nonionic iodinated contrast material rarely develop serious long-term problems and can be treated safely with commonly used medications, according to a study conducted by researchers at the University of Michigan Hospitals in Ann Arbor.Adverse reactions to iodinated contrast agents are rare. Occasionally, however, physicians who administer contrast media to patients may run into these allergy-like reactions, and some will require treatment, said coauthor Dr. Richard H. Cohan. Cohan and colleagues retrospectively reviewed institutional records of all nonionic iodinated agents used for contrast-enhanced CT exams from January 1999 to December 2005. They sought to determine how often reactions occurred, how often they had to be treated, and what happened to patients who underwent treatment.The researchers found that of the 84,928 adult patients who received IV contrast media, only 545 (0.6%) had allergic-like reactions, 221 of whom were treated mostly with antihistamines and other common medications. Overall, 99% of the allergic-like reactions resolved within 24 hours without long-term side effects. The investigators published the study in the August issue of the American Journal of Roentgenology (2008;191:409-415).Of the 545 affected patients, 418 had mild allergy-like reactions, while 116 and 11 suffered moderate or severe reactions, respectively. Most patients were treated with diphenhydramine (145), followed by corticosteroids (17), albuterol (16), ephinephrine (15), and nitroglycerin (8)."Commonly used medications can be administered safely," Cohan said. "However, treatment errors are not uncommon and in a few instances can lead to patient morbidity."
Cohan and colleagues found a number of cases in which nonrecommended treatment was provided:
The most striking example of patient morbidity from nonrecommended treatment occurred in two patients who received doses of 1 mg of epinephrine in the absence of cardiopulmonary arrest and had cardiac complications. These complications were mild and transient, however, and caused no serious morbidity. Radiologists, nurses, and technologists should review the algorithms for treating contrast reactions on a regular basis, he said.
"In fact, we would suggest that such a review should probably occur at least twice a year," Cohan said. "However, it is also consoling to know that even when patients have moderate or severe contrast reactions, the vast majority recover promptly and without any long-term complications."For more information from the Diagnostic Imaging archives:
Contrast-induced nephropathy fears ease
Fast CT scans increase risk of contrast timing errors
Nonionic contrast media prove safe in pediatric patients
Initial research challenges contrast reaction dogma
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.